Version May 2024
Shock: IV: Usual minimum dose: 250 to 500 mL (12.5 to 25 g of protein); adjust dose based on clinical response.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
The following adverse drug reactions are derived from product labeling unless otherwise specified.
Postmarketing:
Cardiovascular: Flushing
Dermatologic: Urticaria
Gastrointestinal: Nausea
Hypersensitivity: Anaphylaxis (McMillin 1978)
Nervous system: Headache
Neuromuscular & skeletal: Back pain
Hypersensitivity to plasma protein fraction or any component of the formulation; patients on cardiopulmonary bypass; severe anemia; heart failure; increased blood volume.
Concerns related to adverse effects:
• Hypotension: Rapid infusions may cause hypotension. Decrease or stop infusion if sudden hypotension occurs.
Dosage form specific issues:
• Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.
Other warnings/precautions:
• Coagulation disorders: Plasma protein fraction does not contain coagulation factors and does not correct coagulation disorders.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intravenous:
Plasmanate: 5% (50 mL, 250 mL)
No
Solution (Plasmanate Intravenous)
5% (per mL): $0.54
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
IV: For IV administration. Administration should begin within 4 hours after piercing the vial; rapid infusion may cause vascular overload. Hypotension may occur when administered at rates >10 mL/minute; decrease rate of infusion if hypotension occurs.
Shock: Treatment of shock due to loss of plasma fluids (eg, shock due to burns, crushing injuries, abdominal emergencies); emergency treatment of shock due to hemorrhage.
None known.
There are no known significant interactions.
Animal reproduction studies have not been conducted.
Blood pressure, pulse, pulmonary exam
Human plasma product to increase blood volume.
Duration: Up to 48 hours
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
